Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study

Bachet, Jean-Baptiste; Wyrwicz, Lucjan; Price, Timothy; Cremolini, Chiara; Phelip, Jean-Marc; Portales, Fabienne; ÖZET, AHMET; ÇİÇİN, İRFAN; Atlan, Dan; Becquart, Martin; Vidot, Loick; Mounedji, Nadjat; Van Cutsem, Eric; Taieb, Julien; Falcone, Alfredo

doi:10.1136/esmoopen-2020-000698

Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study

Atıf İçin Kopyala

Bachet J., Wyrwicz L., Price T., Cremolini C., Phelip J., Portales F., ...Daha Fazla

ESMO OPEN, cilt.5, sa.3, 2020 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 5 Sayı: 3
Basım Tarihi: 2020
Doi Numarası: 10.1136/esmoopen-2020-000698
Dergi Adı: ESMO OPEN
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, Directory of Open Access Journals
Gazi Üniversitesi Adresli: Evet

Özet

Background In RECOURSE (, trifluridine/tipiracil significantly improved overall survival and progression-free survival (PFS) versus placebo in patients with pretreated metastatic colorectal cancer (mCRC). PRECONNECT was designed to further characterise safety and clinical use of trifluridine/tipiracil.